Join
Live feed
·
PRReleasevia Quantisnow
Halozyme Therapeutics Inc. logo

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

ByQuantisnow·Wall Street's wire, on your screen.
HALO· Halozyme Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HALO (Halozyme Therapeutics Inc.) and more on Quantisnow.